Article
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study.
Targeted oncology - 1 Feb 2020
Faloppi Luca, Puzzoni Marco, Casadei Gardini Andrea, Silvestris Nicola, Masi Gianluca, Marisi Giorgia, Vivaldi Caterina, Gadaleta Cosmo Damiano, Ziranu Pina, Bianconi Maristella, Loretelli Cristian, Demurtas Laura, Lai Eleonora, Giampieri Riccardo, Galizia Eva, Ulivi Paola, Battelli Nicola, Falcone Alfredo, Cascinu Stefano, Scartozzi Mario
Abstract excerpt
BACKGROUND: Sorafenib represents one of the therapeutic strongholds for advanced hepatocellular carcinoma (HCC), but unfortunately, predictive factors are lacking. We previously reported that the VEGF single nucleotide polymorphisms (SNPs) rs2010963 and rs4604006 might correlate with clinical outcomes in sorafenib-treated HCC patients. OBJECTIVE: The objective of the ALICE-2 study is to define a prognostic...
Read the complete abstract on PubMed